Show simple item record

dc.contributor.authorChiappini, Stephania
dc.contributor.authorMiuli, Andrea
dc.contributor.authorMosca, Alessio
dc.contributor.authorPettorruso, Mauro
dc.contributor.authorGuirguis, Amira
dc.contributor.authorCorkery, John Martin
dc.contributor.authorMartinotti, Giovanni
dc.contributor.authordi Giannantonio, Massimo
dc.contributor.authorSchifano, Fabrizio
dc.date.accessioned2021-01-21T10:45:22Z
dc.date.available2021-01-21T10:45:22Z
dc.date.issued2021-01-13
dc.identifier.citationChiappini , S , Miuli , A , Mosca , A , Pettorruso , M , Guirguis , A , Corkery , J M , Martinotti , G , di Giannantonio , M & Schifano , F 2021 , ' The benzydamine experience: A systematic review of Benzydamine abuse ' , Current neuropharmacology . https://doi.org/10.2174/1570159X19666210113151136
dc.identifier.issn1570-159X
dc.identifier.otherPURE: 24154707
dc.identifier.otherPURE UUID: 67951170-b6fc-46c4-a3a3-ee5767e7b423
dc.identifier.urihttp://hdl.handle.net/2299/23724
dc.descriptionSubmitted 25 August 2020. Revised 14 December 2020. Accepted 19 December 2020.
dc.description.abstractBackground: Both prescription and over-the-counter (OTC) drugs recently emerged among novel psychoactive substances (NPS) being reported as ingested for recreational purposes. Among them, benzydamine (BZY), normally prescribed as an OTC anti-inflammatory drug, is reportedly being diverted and recreationally used. Objective: The aim of this study was to investigate how the misuse of BZY has been reported, illustrating its psychotropic molecular mechanism, and studying its psychopathological effects. Methods: We firstly conducted a systematic review of the literature concerning the abuse of BZY and its effects. For data gathering purposes, both PRISMA and PROSPERO guidelines were followed. All research methods were approved by PROSPERO (identification code CRD42020187266). Second, we analysed BZY-related data from the European Monitoring Agency (EMA) Adverse Drug Reactions (ADRs) database recorded during 2005-2020 regarding its abuse. Results: Eleven articles, published during 1997-2019, were included in our systematic review, including five case reports, four surveys, and two retrospective case series analyses. While nine articles dealt with a recreational use of BZY, two described an oral overdose of the drug. When specified, dosages of BZY consumed ranged from 500 to 1500mg. The EMA dataset contained three cases of BZY abuse. Conclusion: Results from the systematic review showed BZY might be diverted for typical hallucinogenic properties which occur at high dosages. Healthcare professionals should be warned about a possible misuse/abuse of a commonly prescribed anti-inflammatory drug and be vigilant when prescribing it. Physicians working in emergency units should know that psychotic symptoms may be related to BZY abuse.en
dc.language.isoeng
dc.relation.ispartofCurrent neuropharmacology
dc.subjectbenzydamine
dc.subjectbenzydamine misuse
dc.subjectover-the-counter drug abuse
dc.subjectNPS
dc.subjectNovel Psychoactive Substances
dc.titleThe benzydamine experience: A systematic review of Benzydamine abuseen
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.date.embargoedUntil2022-01-13
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.2174/1570159X19666210113151136
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record